Japan 5-fluorouracil (5-FU)-based regimens provide superior survival and quality of life in patients with advanced gastric cancer when compared with the best supportive care [1] [2] [3] . However, this survival advantage appears to be marginal, and no standard regimens worldwide have been established yet.
Introduction
Unresectable advanced or recurrent gastric cancer still has a poor prognosis, with a median survival of less than 9 months. Randomized trials demonstrated that studies were limited with a median survival time (MST) ranging from 6 to 8 months and no confirmation of superiority of ECF over two-drug combinations such as cisplatin (CDDP) plus 5-FU (CF). Other trials including using 5-FU alone as a reference arm and comparing it with FU-based combination regimens have been reported from the United States, Korea, and Japan [7] [8] [9] . All three trials showed similar results: combination regimens failed to demonstrate survival prolongations as compared with 5-FU alone, while response rates and progression-free survival in the CF arm were superior to single-agent 5-FU.
Based on the results of these randomized trials, CF could be a reasonable reference arm. However, even this regimen has not shown superiority to 5-FU alone in terms of overall survival, and there still are limitations on efficacy results in older-generation regimens: the response rates ranged from 10% to 35%, and the MSTs from 6 to 8 months with around 10% in 2-year survival. To overcome these limitations, new active agents were essential.
Current status of new-generation regimens

Single-agent studies
Recently, new-generation agents such as irinotecan, S-1, capecitabine, docetaxel, paclitaxel, and oxaliplatin have been developed and investigated for gastric cancer with promising activities [10] [11] [12] [13] [14] [15] . Results of single-agent studies are summarized in Table 2 . Of the five agents, S-1 achieved the highest response rate, 45%; and the other agents also showed moderate activity, with response rates of 18% to 34%. These active agents are now being investigated in combination with other agents.
Combination studies (Tables 3, 4)
Irinotecan and its combinations
Irinotecan is an inhibitor of DNA-topoisomerase I, which is a crucial enzyme involved in DNA replication and transcription. At first this agent was investigated in combination with CDDP in Japan [16, 17] . A phase II study of this combination (irinotecan at 70 mg/m 2 , day 1 and 15, and CDDP at 80 mg/m 2 , day1 every 4 weeks) achieved a high response rate of 48% with an MST of 9 months in all patients, and of 59% with an MST of 11 months in chemonaive patients. Toxicities were substantial, the major ones being neutropenia and diarrhea: grade 4 neutropenia was observed in 57% of patients and grade 3 or 4 diarrhea in 20%. This combination has been modified to a weekly schedule in order to reduce toxicity and has been followed in Western countries. Both of the phase II studies in the United States showed similar activity, with response rates of 58% and 57% [18, 19] . This combination is now being investigated in a randomized phase III trial in Japan.
Another combination was conducted with mitomycin C; the phase I/II study of this combination revealed similar efficacy results and less toxicity than an irinotecan/CDDP regimen [20] . This regimen was then evaluated in the phase II study as a second-line setting after the failure of FU-based regimens [21] . Of the 45 patients registered, 13 achieved partial response, with a response rate of 29%. Median progression-free survival was 4 months. Toxicities were moderate: grade 4 neutropenia was observed in 29% of patients and grade 3 anorexia in 24%. This study concluded that this regimen could be a treatment option in patients resistant to an FU-based regimen.
Oral fluoropyrimidines and their combinations S-1 is a new oral fluoropyrimidine consisting of three components: tegafur, which is a prodrug of 5-FU; 5-chloro-2,4-dihydroxypyridine (CDHP), which competes with dihydropyrimidine dehydrogenase; and oxonic acid, which suppresses the gastrointestinal toxicity of tegafur. Various attempts in combination with other agents such as CDDP, irinotecan, and taxanes have been conducted, particularly in Japan. At first, this agent was combined with CDDP. This combination phase I/II study was scheduled as S-1 40 mg/m 2 twice daily for 21 consecutive days and 2-h infusion of CDDP at 60-70 mg/m 2 on day 8, which was repeated every 5 weeks [22] . This study revealed an excellent response rate of 76% with an MST of 12.6 months. Toxicities were moderate but easily manageable: grade 3 or 4 hematological and nonhematological toxicities were 15.8% and 26.3%, respectively. Another combination, S-1ϩCPT-11, is also promising. A phase I/II study of this combination revealed similar response rates of around 50% with an MST of 14 months [23] .
In spite of the promising results in Japan, the development of this agent in Western countries has been interrupted due to severe diarrhea as a side effect. The first European single-agent phase II study had to be decreased from 40 to 35 mg/m 2 owing to significant diarrhea [24] . These differences might be caused by higher susceptibility to diarrhea or lower absorption of oxonic acid in Western populations [25] . However, this agent is now being retested using lower doses in the United States. Ajani et al. reported a phase I study of S-1 in combination with CDDP [26] . The predominant doselimiting toxicities were fatigue, diarrhea, and mucositis. Although the maximum tolerated dose of the study (S-1 at 25 mg b.i.d for 3 weeks and CDDP at 75 mg/m 2 every 4 weeks) was different from that of the Japanese study, the preliminary results were promising and a phase II study is now underway in the United States.
The activity of capecitabine for gastric cancer has also been reported, particularly from Korea. This agent , day 1, repeated every 3 weeks, which resulted in a high response rate of 68% (27/40) with a long MST of 17 months [29] . These results warrant further investigations of these capecitabine-based combinations and should be evaluated in large-scale randomized trials.
Taxanes and their combinations
The taxanes docetaxel and paclitaxel inhibit microtubule depolymerization and have moderate activity against gastric cancer, with a response rate of around 20% in single-agent studies. Paclitaxel was combined with a CF regimen in the Korean phase II study [30] . Although this three-drug combination achieved a high response rate of 51% (21/41), an MST of 6 months seemed disappointing. The Swiss Group for Clinical Cancer Research has reported a phase II study of docetaxel 85 mg/m 2 with CDDP 75 mg/m 2 administered once every 3 weeks for advanced gastric cancer, achieving a response rate of 52%, median time to progression of 6.6 months, and an MST of 9 months [31] . This combination was then followed by three-drug combinations adding 5-FU and has been investigated in the randomized trial described later.
Oxaliplatin and its combinations
Oxaliplatin is an alkylating agent inhibiting DNA replication by forming adducts between two adjacent guanines or guanine and adenine molecules. With the success of the combination of oxaliplatin and 5-FU/ leucovorin (LV) for colorectal cancers, this combination was tested for gastric cancer. Louvet et al. reported a phase II study of oxaliplatin in combination with infusional 5-FU/LV (FOLFOX6) for advanced or metastatic gastric cancer, which resulted in a response rate of 45% and an MST of 8.6 months [32] . However, FOLFOX6 caused significant toxicity including myelosuppression and peripheral neuropathy. Subsequently the regimen was revised with a reduced dose of oxaliplatin and without bolus infusion of 5-FU. The revised phase II revealed a similar response rate and MST of 9.6 months, with less toxicity than those in the previous study [33] . The authors concluded that the modified FOLFOX6 regimen provided efficacy results comparable with other combination regimens with significantly less toxicity.
Randomized controlled trials including newer-generation regimens
As mentioned above, various combination regimens including new agents showed promising results in the phase II studies, with response rates of around or above 50%. Most of the new-generation regimens are now being evaluated to determine whether they would provide significant survival prolongations as compared with older-generation regimens (Table 5) . Recently, an international randomized controlled trial (V-325) comparing a docetaxel-based regimen with the reference regimen of CF was reported following an interim analysis [34] . The phase II randomized portion of the study revealed an overall response rate of 28% with docetaxel/CDDP, and of 43% with docetaxel/CDDP/5-FU (DCF). Subsequently the DCF regimen was chosen as the experimental arm for the phase III stage. The doses and schedule of the DCF arm were: docetaxel 75 mg/m 2 on day 1, CDDP 75 mg/m 2 on day 1, and 5-FU 750 mg/m 2 per day as continuous infusion on days 1-5, repeated every 3 weeks. The dose and schedule of the CF arm were CDDP 100 mg/m 2 day 1 and 5-FU 1000 mg/m 2 per day as continuous infusion on days 1-5, administered every 4 weeks. At the interim analysis on 232 patients, time to progression was superior (P ϭ 0.0008) for DCF (5.2 months vs 3.7 months for CF). The MST was also longer for patients receiving DCF (10.2 months) than for those receiving CF (8.5 months). Neutropenic fever, infections, diarrhea, and mucositis were also higher from DCF than from CF. To date, however, the interpretation of the V-325 study results appears to be controversial. Although this study confirmed the superiority of DCF over CF in terms of efficacy, the MST of the DCF arm was 10.2 months, which did not seem a marked improvement. The latest combination studies, as listed in Tables 3 and 4 , yielded 12 months or longer MST, although patient numbers were low. Additionally, toxicity of DCF was significant, with grade 3/4 neutropenia of 84%. The decision of whether the superiority of DCF can be accepted should wait until publication of final results. Another international randomized phase II/III study (V306), which compared irinotecan/CDDP with irinotecan plus infusional 5-FU/leucovorin in the phase II portion is now under investigation, mostly in European countries [35] . In that study, 200 mg/m 2 of irinotecan and 60 mg/m 2 of CDDP were administered every 3 weeks, compared with 80 mg/m 2 of irinotecan, 500 mg/m 2 of folinic acid (leucovorin, LV), and 2000 mg/ m 2 of 5-FU as a 24-h infusion per week for 6 weeks followed by 1 week of rest. The overall response rates and MSTs of irinotecan/CDDP and irinotecan/5-FU/LV were 32% and 42% and 6.9 and 10.7 months, respectively. Toxicity results also revealed more favorable profiles in irinotecan/5-FU/LV than in irinotecan/ CDDP; therefore, the former regimen has been chosen as the experimental arm for the phase III portion in comparison with the control arm of CF. Superiority of the irinotecan/5-FU/LV has also been observed in a French randomized phase II study comparing 5-FU/LV with CDDP/5-FU/LV and with irinotecan/5-FU/LV [36] . These two randomized phase II studies suggest that irinotecan/5-FU/LV is the most promising combination regimen; however, confirmation by a phase III study is necessary. In Europe, there is another ongoing study with oxaliplatin used in combination with epirubicin and capecitabine. Patients are randomly assigned to one of the four regimens: ECF (epirubicin/ CDDP/5-FU), EOF (epirubicin/oxaliplatin/5-FU), ECX (epirubicin/CDDP/capecitabine), and EOX (epirubicin/oxaliplatin/capecitabine). The preliminary results available in 2003 showed response rates of 31%, 33%, 35%, and 52% for ECF, EOF, ECX, and EOX, respectively [37] . Complete results will be expected in the near future. The fourth trial is now underway in Asian countries, mostly in Korea, in a study comparing 5-FU/CDDP with capecitabine/CDDP.
In the meantime, many randomized trials consisting of an S-1 based regimen are now being evaluated in Japan. Based on the results of JCOG9205 [9] , the JCOG considered single-agent 5-FU as the reference arm and has initiated three-arm randomizations (JCOG9912) comparing 5-FU alone with a combination of irinotecan/CDDP and with S-1 alone. This study requires a sample size of 690 and the accrual will be completed at the end of 2005. The second study is a postmarketing randomized trial comparing S-1 alone with S-1ϩCDDP (sponsored by the Taiho Pharmaceutical Company), with a sample size of 300. The accrual to this study has been recently completed. The other studies are also designed to have S-1 as the reference arm: S-1 versus 5-FU/LV sponsored by Weiss, and S-1 versus S-1/irinotecan sponsored by the Yakult-Daiichi Pharmaceutical Company.
There may be significant differences between Japan and other countries in interpreting the reference arm. Most countries consider CF, some regions ECF, as the reference arm for metastatic gastric cancer. However, single-agent 5-FU is considered the reference arm in JCOG based on the results of the previous randomized trial (JCOG9205) as well as the Korean and North American trials [7] [8] [9] , and S-1 monotherapy has been selected as the reference arm in the later trials in Japan. This difference was caused by the different interpretation of the trials comparing single-agent 5-FU with CF, different histories of randomized trials, and cultural differences between the regions. One might say that high response rate and long progression-free survival would provide better quality of life, but another could say that 5-FU alone would provide the same survival as CF, with less toxicity, which seemed to provide better quality of life. In addition, there might be some questions raised: whether combination regimens as front-line therapy have survival advantages over single-agent therapy; determining which is better, simultaneous or sequential combinations; and whether we have to change the primary end point to progression-free survival rather than overall survival. The above ongoing trials will answer these questions, and the MST of the new standard should exceed 11 months to be considered a definite improvement. Contrary to the recent advances in colorectal cancer, no confirmation of improving results with newer-generation regimens as compared with older-generation ones has been achieved yet. It is likely that at first we should confirm definite overall survival prolongation.
Randomized trials in patients with peritoneal metastasis
The peritoneum is the major site of metastasis from gastric cancer. However, patients with peritoneal metastasis usually are in poor general condition, with impairment of oral intake and complications such as bowel obstruction and hydronephrosis, which may prolong elimination of the agents. Patients with peritoneal dis-semination are excluded from a phase II study because these studies usually require response evaluation as a primary end point, whereas these patients usually have no measurable lesions. Thus, a specifically targeted study should be conducted. A phase II study of sequential combination of methotrexate (MTX) plus 5-FU (JCOG9603) has been carried out in patients with malignant ascites [38] . A total of 37 patients were registered; remarkable decreases of ascites were observed in 13 patients (35%), including 4 (11%) with disappearance of ascites, while 2 (5%) patients died of treatmentrelated toxicity. Based on the results, a phase III study comparing 5-FU alone with MTX/5-FU (JCOG0106) in patients with peritoneal dissemination has been initiated in the JCOG and the accrual will be completed in 2005. Another randomized trial to investigate an efficacy of paclitaxel for this disease is now being conducted as a second-line therapy in JCOG.
Molecular targeting agents under investigation
Recently developed molecular targeting agents may provide a significant impact in this field, as successful results of bevacizumab and cetuximab have been observed in colorectal cancer [39, 40] .
Gefitinib is an orally active epidermal growth factor receptor-tyrosine kinase inhibitor that has shown single-agent action against non-small-cell lung cancer. A Japan-Europe joint phase II study was conducted to investigate the efficacy, tolerability, and pharmacokinetics of gefitinib in patients with metastatic gastric adenocarcinoma [41] . Seventy-five patients (32 Japanese, 43 non-Japanese) were randomized to receive 250 mg/ day or 500 mg/day gefitinib orally. Disease control was achieved in 13 patients: 1 (250 mg/day) had a partial response and 12 had stable disease (4 at 250 mg/day, 8 at 500 mg/day), with a disease control rate of 18%. The most common drug-related adverse events were diarrhea (45.9%), rash (35.1%), and anorexia (12.2%). Drug-related grade 3/4 adverse events were experienced by 11.1% and 23.7% of patients given 250 mg/day and 500 mg/day gefitinib, respectively. Gefitinib exposure appeared to be unaffected by ethnicity or previous gastric surgery. Furthermore, there was no marked difference in plasma concentration in patients with disease control (partial response plus stable disease) versus progressive disease. In conclusion, gefitinib monotherapy was generally well tolerated but its action seemed to be limited.
Investigations of two other molecular targeting agents are now being planned. EMD72000 is a 95% humanized monocloncal antibody against EGFR that showed promising activity for colorectal adenocarcinoma in a phase I study [42] . This agent has less toxicity, particularly in allergic reaction and skin rash, than cetuximab, which is a chimeric antibody against EGFR. This agent in combination with a cytotoxic agent will be evaluated in patients with EGFR-positive gastric cancer. Another planned agent is trastuzumab, a monoclonal antibody to Her2 protein, which is widely used in patients with Her2-overexpressing breast cancer. We have evaluated the frequency of Her2 overexpression and the concordance between protein expression and gene amplification in 200 surgical and endoscopic biopsy specimens using two commercial immunohistochemical (IHC) kits (Dako Cytomation, Glostrup, Denmark) and fluorescence in situ hybridization (FISH) (VYSIS, Abbott Laboratories, Downers Grove, IL, USA) [43] . Among these 200 cases, 46 (23%) of the patients were found to exhibit Her2 protein overexpression. The following IHC scores were obtained: 0: 126 (63%); 1ϩ: 28 (14%); 2ϩ: 12 (6%); and 3ϩ: 34 (17%). Gene amplification examined with FISH was observed in 54 cases (27.1%). Her2 protein overexpression was observed in 21.5% of the 200 biopsy specimens (2ϩ: 7.5%; 3ϩ: 14%). The concordance rate between the surgically resected materials and the biopsy specimens was 88.7%. From these background results, trastuzumab can be applied for clinical trial in patients with Her 2 overexpressed gastric cancer, and a randomized trial is now being conducted as an international study.
Although the efficacy of the molecular targeting agents is still limited, these agents are the other new hopes for improving efficacy results with less toxicity than conventional cytotoxic agents. Understanding of the biology of gastric cancer may result in better targets or cellular pathways being modified or blocked by therapeutic interventions. Additionally, improvement of the clinical trial design and molecular surrogate into clinical research will lead to the development of better treatments. Both clinical and biological research will be more important.
